Catalyst
Slingshot members are tracking this event:
Johnson & Johnson (JNJ) subsidiary Janssen releases Phase 3 study on Xarleto versus aspirin in treating recurrent blood clots without increase in bleeding in Venous Thromboembolism patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| JNJ | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 18, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aspirin, Phase 3, Xarleto, Recurrent Blood Clots
